RDY vs. TEM: Dr. Reddy's Laboratories vs. Tempus AI Stock Comparison

Company Profile

Dr. Reddy's Laboratories (RDY) and Tempus AI (TEM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but RDY is classified in Pharmaceuticals while TEM is classified in Life Sciences Tools & Services.

Dr. Reddy's Laboratories (RDY) carries decades of public-market history since April 11, 2001, while Tempus AI (TEM) listed on June 14, 2024 — long-window comparisons have far more historical data on the RDY side.

Tempus AI (TEM) trades as ordinary local shares, while Dr. Reddy's Laboratories (RDY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Tempus AI (TEM) has a highly aggressive beta of 3.34, indicating much higher sensitivity to broad-market moves, while Dr. Reddy's Laboratories (RDY) is defensive at 0.30 and tends to be less market-sensitive — a wide gap in beta profiles.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Tempus AI (TEM) reports a negative ROE of -37.55%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Dr. Reddy's Laboratories (RDY) reports 7.34%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative net margin of -12.54%, usually indicating a net loss over the period. Meanwhile Dr. Reddy's Laboratories (RDY) reports 8.49%, ranking against industry peers normally.

Tempus AI (TEM) reports a negative operating margin of -13.82%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Dr. Reddy's Laboratories (RDY) reports 14.73%, ranking against industry peers normally.

Profitability Metrics

Growth

Tempus AI (TEM) at 83.41% sits in the top revenue growth quartile, while Dr. Reddy's Laboratories (RDY) at 3.19% is closer to the peer norm — faster top-line expansion for TEM.

Only one side can be read here: Dr. Reddy's Laboratories (RDY) reports EPS growth of -24.14%, ranked against its industry; Tempus AI (TEM) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Tempus AI (TEM) at 2.61 keeps current ratio within its industry’s typical mid-range, while Dr. Reddy's Laboratories (RDY) at 1.93 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for RDY.

Dr. Reddy's Laboratories (RDY) at 0.19 is near its industry mid-range for debt-to-equity ratio, while Tempus AI (TEM) at 2.86 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Tempus AI (TEM) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Dr. Reddy's Laboratories (RDY) reports a yield of 55.06%, ranking against industry peers normally.

Tempus AI (TEM) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Dr. Reddy's Laboratories (RDY) reports a payout of 22.72%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Dr. Reddy's Laboratories (RDY) trades at 41.42 times trailing earnings, ranked against its peers, while Tempus AI (TEM) has no P/E ratio this period.

Dr. Reddy's Laboratories (RDY) at 0.04 sits in the cheaper P/S ratio quartile while Tempus AI (TEM) at 9.19 prices around its industry’s middle — RDY costs less per dollar of sales, though read it alongside growth and margins.

Measured against book value, both Dr. Reddy's Laboratories (RDY) at 18.16 and Tempus AI (TEM) at 27.66 look expensive — each P/B ratio sits above its industry’s benchmark range.

Valuation Metrics